ResMed stock heads into the open after a 4.5% Nasdaq gain
Published on 09/16/2026 at 06:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed stock closed at about USD 232.99 on Nasdaq on September 15, 2026, up roughly 4.5% from a prior close of USD 222.99, according to U.S. exchange data cited by MarketBeat and Investing.com. The move left ResMed ahead of the broader S&P 500 index, which posted a more modest percentage gain for the same session.
September 15, 2026 in numbers
ResMed Inc. (ISIN US7611521078, NYSE: RMD) shares traded during the September 15, 2026 session in a range that ran from around USD 223 at the low to an intraday high near USD 233.23, with roughly 420,000 shares changing hands, meaning volume came in about 68% below the company’s recent average daily level, according to closing data and commentary from MarketBeat. The September 15, 2026 close near USD 232.99 left the stock several percent below its 52-week high yet comfortably above recent lows, keeping ResMed within the upper half of its documented 52-week trading range.
Analyst action was a clear driver for the session. As Investing.com reported on September 15, 2026, RBC Capital Markets raised its rating on ResMed from Sector Perform to Outperform and lifted the firm’s price target to USD 262 from USD 244. The note highlighted double-digit volume growth in key sleep-device markets and argued that the company can sustain high single-digit earnings-per-share growth over the next several years, while also pointing to an FDA class 1 recall of a competing sleep device as a potential tailwind for ResMed’s product demand. That upgrade, together with earlier positive commentary from other houses, helped ResMed shares outperform major health care peers on September 15, 2026.
Today’s factors for ResMed stock
Today, September 16, 2026, ResMed heads into the open without a scheduled earnings release or annual shareholder event falling on the calendar, but investors continue to digest the implications of the RBC Capital Markets upgrade and recent conference commentary. As TradingView summarized in a transcript of ResMed’s appearance at the Morgan Stanley Global Healthcare Conference on September 15, 2026, management emphasized volume-driven growth, ongoing margin improvement and portfolio shifts toward digital and cloud-based solutions, themes that can continue to shape sentiment on the stock today. Broader moves in U.S. health care indices and any follow-up analyst commentary on the RBC upgrade or conference takeaways may also influence how ResMed trades in the upcoming session.
